GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
GILEAD SCIENCES, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$153.07−3.12 (-2.00%)
Close on Oct 19, 2026
- Market cap
- $190.27B
- P/E (TTM)
- –
- Dividend yield
- 2.06%
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
78.8%−2.7 pts over 5 years
Operating margin
34.0%+17.5 pts over 5 years
Net margin
28.9%+28.4 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +2.4% | +2.6% | +3.6% | -1.0% | |
| Gross profit | +3.1% | +2.4% | +2.9% | -2.1% | |
| Operating income | +503.0% | +11.0% | +19.7% | -7.6% | |
| Net income | +1672.9% | +22.8% | +133.3% | -7.3% | |
| EPS, diluted | +1684.2% | +23.0% | +132.4% | -5.5% | |
| Free cash flow | -8.2% | +4.3% | +4.7% | -7.4% | |
| Dividend per share | +2.6% | +2.7% | +3.0% | +9.4% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 72.2% | 0.6% | 40.5% | |
| Return on assets | 24.8% | 0.2% | 14.4% | |
| Current ratio | 2.12 | 1.40 | 1.55 | |
| Debt to equity | 1.39 | 1.73 | 1.10 | |
| Interest coverage | 18.3× | 4.1× | 9.8× | |
| Inventory turnover | 2.4× | 3.5× | 3.6× | |
| Capex to revenue | 2.5% | 2.6% | 1.9% | |
| Diluted shares | 1.36B | 1.26B | 1.25B |
Where the cash went
Fiscal 2021 to 2025, five years combined
Gilead Sciences generated $49.31B from operations and spent $28.04B on capital expenditure, dividends and share buybacks. 11% of that went back into the business.
Generated
$49.31B
Used
$28.04B
Capital expenditure$2.98B11%Dividends$19.04B68%Share buybacks$6.01B21%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin28.9%
×Asset turnover0.50×
×Equity multiplier2.81×
=Return on equity, FY202540.5%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 28.9% | 0.50× | 2.81× | 40.5% |
| FY2024 | 1.7% | 0.47× | 2.87× | 2.3% |
| FY2023 | 20.9% | 0.43× | 2.84× | 25.7% |
| FY2022 | 16.8% | 0.42× | 3.10× | 21.7% |
| FY2021 | 22.8% | 0.40× | 3.47× | 31.7% |
| FY2020 | 0.5% | 0.38× | 3.19× | 0.6% |
| FY2019 | 24.0% | 0.36× | 2.85× | 24.5% |
| FY2018 | 24.7% | 0.33× | 3.20× | 26.1% |
| FY2017 | 17.7% | 0.41× | 3.24× | 23.5% |
| FY2016 | 44.4% | 0.56× | 2.90× | 72.2% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
8of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero$8.51B
- Cash generatingOperating cash flow above zero$10.02B
- Return on assets improvedROA up on the prior year0.8% → 14.4%
- Earnings backed by cashOperating cash flow above net income$10.02B vs $8.51B
- Less leverageLong-term debt to assets fell42.2% → 37.5%
- Better liquidityCurrent ratio rose1.60 → 1.55
- No dilutionShare count did not rise1.25B → 1.25B
- Gross margin improvedGross margin up on the prior year78.26% → 78.83%
- More efficientAsset turnover rose0.46 → 0.50